CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris

Summary

This is an investigator-initiated, single-center, single-arm, open-label exploratory clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris.

Timeline

Start

2026-01-15

Primary completion

2026-12-30

Completion

2028-12-30

Drugs

Indications